Biology of Lung Cancer With Implications for New Therapies

Marie F. Aberle

Sandra W. McLeskey

ONF 2003, 30(2), 273-280. DOI: 10.1188/03.ONF.273-280

Purpose/Objectives: To provide an overview of the biology of lung cancer with respect to genetic carcinogenesis and specific mutations and to discuss new therapies being developed to target lung cancer's biologic processes.

Data Sources: Published articles, abstracts, book chapters, lectures, and personal experiences with experimental agents.

Data Synthesis: Lung cancer is the number one cause of cancer deaths for men and women in the United States, with minimal changes in the five-year survival rate during the past decade. New understanding of the biologic process of lung cancer is providing potential new therapies that many hope will lead to increased survival for patients with lung cancer.

Conclusions: Exciting new therapies for lung cancer are being developed that target specific biologic processes of lung cancer.

Implications for Nursing: When nurses are familiar with the rationale behind biologic therapies, they can understand the drugs, assess toxicities, and help patients make educated decisions about therapeutic alternatives.

Jump to a section

    References

    American Cancer Society. (2003). Cancer facts and figures 2003. Retrieved January 21, 2003, from http://www.cancer.org/downloads/STT/CAFF2003PWSecured.pdf

    Baringa, M. (1997). Treatment marks cancer cells for death. Science, 278, 1037-1039.

    Bunn, P., Soriano, A., Johnson, G., & Heasley, L. (2000). New therapeutic strategies for lung cancer: Biology and molecular biology come of age. Chest, 117(4 Suppl. 1), 163S-168S.

    Cox, A. (2001). Farnesyl transferase inhibitors: Potential role in the treatment of cancer. Drugs, 61, 723-732.

    Devereux, T., Taylor, J., & Barrett, J. (1996). Molecular mechanisms of lung cancer: Interaction of environmental and genetic factors: Giles F. Filley lecture. Chest, 109(3 Suppl.), 14S-19S.

    Eskens, F., Stoter, G., & Verwelij, J. (2000). Farnesyl transferase inhibitors: Current developments and future perspectives. Cancer Treatment Reviews, 26, 319-332.

    Fong, K., Sekido, Y., & Minna, J. (1999). Molecular pathogenesis of lung cancer. Journal of Thoracic and Cardiovascular Surgery, 118, 1136-1152.

    Ginsberg, R., Vokes, E., & Rosenweig, K. (2001). Non-small cell lung cancer. In V. DeVita, S. Hellman, & S. Rosenberg, (Eds.) Cancer: Principles and practice of oncology (6th ed., pp. 925-975). Philadelphia: Lippincott Williams and Wilkins.

    Green, M., Murray, J., & Hortobagyi, G. (2000). Monoclonal antibody therapy for solid tumors. Cancer Treatment Reviews, 26, 269-286.

    Greenlee, R., Hill-Harmon, M., Murray, T., & Thun, M. (2001). Cancer statistics, 2001. CA: A Cancer Journal for Clinicians, 51, 15-36.

    Hess, K., & Abbruzzese, J. (2001). Matrix metalloproteinase inhibition of pancreatic cancer: Matching mechanism of action to clinical trial design. Journal of Clinical Oncology, 19, 3445-3446.

    Hodgson, S., & Maher, E. (1999). A practical guide to human cancer genetics (2nd ed.). Cambridge, UK: Cambridge University Press.

    Korrapati, V., Gaffney, M., Larson, L., Di Nunno, L., Riggs, M., Reissner, R., et al. (2001). Effect of HER2/neu expression on survival in non-small cell lung cancer. Lung Cancer, 2, 216-219.

    Rowinsky, E. (2001). Epidermal growth factor (EGFR) tyrosine kinase as a target for antitumor therapy: Experience with "Iressa" (ZD18390). Retrieved September 19, 2001, from http://mssmtv.org/chemo/webcast/abstracts

    Sekido, Y., Fong, K., & Minna, J. (2001). Cancer of the lung. In V. DeVita, S. Hellman, & S. Rosenberg, (Eds.) Cancer: Principles and practice of oncology (6th ed., pp. 917-925). Philadelphia: Lippincott Williams and Wilkins.

    Sekine, I., & Saijo, N. (2001). Growth-stimulating pathways in lung cancer: Implications for targets of therapy. Clinical Lung Cancer, 1, 299-306.

    Stetler-Stevenson, S., & Kleiner, D. (2001). Molecular biology of cancer: Invasion and metastases. In V. DeVita, S. Hellman, & S. Rosenberg, (Eds.) Cancer: Principles and practice of oncology (6th ed., pp. 123-135). Philadelphia: Lippincott Williams and Wilkins.

    Templeton, D., & Weinberg, R. (2001). Principles of cancer biology. In R. Lenhard, R. Osteen, & T. Gansler, (Eds.) The American Cancer Society's clinical oncology (pp. 165-177). Atlanta, GA: American Cancer Society.

    Yuspa, S., & Shields, P. (2001). Etiology of cancer: Chemical factors. In V. DeVita, S. Hellman, & S. Rosenberg, (Eds.) Cancer: Principles and practice of oncology (6th ed., pp. 179-191). Philadelphia: Lippincott Williams and Wilkins.